Table 3.
Risk of Neurologic Disorders Developing During Follow-Up Among Patients With and Without BP
| Neurologic Disorder | Patients Without BPa |
Patients With BPa |
HR (95% CI)b |
P Value |
|---|---|---|---|---|
| Dementia | 34/230 (15) | 10/78 (13) | 1.25 (0.61–2.55) | .54 |
| Parkinson disease | 2/251 (1) | 4/84 (5) | 8.56 (1.55–47.25) | .01 |
| MS | 1/257 (<1) | 0/86 (0) | NA | .64c |
| Cerebrovascular disease | 10/241 (4) | 6/82 (7) | 2.54 (0.92–7.05) | .07 |
| Seizures | 1/252 (<1) | 1/84 (1) | 5.56 (0.35–88.93) | .23 |
| Any of the above | 41/192 (21) | 19/67 (28) | 2.02 (1.17–3.49) | .01 |
| Dementia or Parkinson disease | 36/220 (16) | 14/75 (19) | 1.64 (0.88–3.06) | .12 |
| Dementia, Parkinson disease, or MS | 37/216 (17) | 14/74 (19) | 1.58 (0.85–2.95) | .15 |
| Dementia, Parkinson disease, MS, or cerebrovascular disease | 43/201 (21) | 19/70 (27) | 1.90 (1.10–3.26) | .02 |
Abbreviations: BP, bullous pemphigoid; HR, hazard ratio; MS, multiple sclerosis; NA, not applicable.
a
Values are No. of patients/No. of patients assessed (%).
b
Risk of neurologic disorder developing during follow-up for patients with BP compared with patients without BP.
c
Log-rank test.